KANSAS CITY, Kan.
Jan. 29, 2014
/PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced the full exercise of the underwriters' option to purchase 975,000 additional shares of common stock in connection with the company's previously announced public offering of 6,500,000 shares of common stock. The additional shares are comprised of 150,000 shares of common stock being sold by Aratana and 825,000 shares of common stock being sold by a selling stockholder. With the exercise of the underwriters' option, gross proceeds to Aratana from the offering are expected to be
, before deducting underwriting discounts and commissions and other offering expenses payable by Aratana Therapeutics.
Jefferies LLC, Barclays, and
are acting as joint book-running managers for the offering. JMP Securities and Craig-Hallum Capital Group are acting as co-managers.
A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.
The offering is being made only by means of a written prospectus forming part of the effective registration statement. Copies of the prospectus related to the offering may be obtained, when available, from Jefferies LLC, c/o Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th FL,
New York, NY
, (877) 547-6340; or Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
11717, Attention: Prospectus Department,
, (888) 603-5847; or
, Attention: Prospectus Department, 222 West Adams Street,
, telephone: (800) 621-0687.
Tiberend Strategic Advisors, Inc.
; (212) 375-2664
; (212) 375-2694
SOURCE Aratana Therapeutics, Inc.